Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer

Autor: Foucauld Chamming's, Thomas Guilbert, Virginie Mieulet, Elisabetta Marangoni, Anne Vincent-Salomon, Fatima Mechta-Grigoriou, Yann Kieffer, Fariba Nemati, Camille Garnier, Gilles Renault

Publikováno v: Scientific Reports
Scientific Reports, 2021, 11 (1), pp.4219. ⟨10.1038/s41598-021-83685-0⟩
Scientific Reports, Vol 11, Iss 1, Pp 1-20 (2021)

Women diagnosed with high-grade serous ovarian cancers (HGSOC) are still likely to exhibit a bad prognosis, particularly when suffering from HGSOC of the Mesenchymal molecular subtype (50% cases). These tumors show a desmoplastic reaction with accumu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ebc6698c39c3864f71f7f005ae0bdd1
https://ut3-toulouseinp.hal.science/hal-03778944

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Autor: Lieske H. Schrijver, Antonis C. Antoniou, Håkan Olsson, Thea M. Mooij, Marie-José Roos-Blom, Leyla Azarang, Julian Adlard, Munaza Ahmed, Daniel Barrowdale, Rosemarie Davidson, Alan Donaldson, Ros Eeles, D. Gareth Evans, Debra Frost, Alex Henderson, Louise Izatt, Kai-Ren Ong, Valérie Bonadona, Isabelle Coupier, Laurence Faivre, Jean-Pierre Fricker, Paul Gesta, Klaartje van Engelen, Agnes Jager, Fred H. Menko, Marian J.E. Mourits, Christian F. Singer, Yen Y. Tan, Lenka Foretova, Marie Navratilova, Rita K. Schmutzler, Carolina Ellberg, Anne-Marie Gerdes, Trinidad Caldes, Jacques Simard, Edith Olah, Anna Jakubowska, Johanna Rantala, Ana Osorio, John L. Hopper, Kelly-Anne Phillips, Roger L. Milne, Mary Beth Terry, Catherine Noguès, Christoph Engel, Karin Kast, David E. Goldgar, Flora E. van Leeuwen, Douglas F. Easton, Nadine Andrieu, Matti A. Rookus, Lilian Laborde, Pauline Pontois, Emanuelle Breysse, Margot Berline, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Chrystelle Colas, Olivier Caron, Emmanuelle Mouret-Fourme, Claire Saule, Christine Lasset, Sophie Dussard, Pascaline Berthet, Elisabeth Luporsi, Véronique Mari, Laurence Gladieff, Stéphanie Chieze-Valéro, Jessica Moretta, Hagay Sobol, François Eisinger, Cornel Popovici, Michel Longy, Louise Grivelli, Florent Soubrier, Patrick Benusiglio, Pascal Pujol, Carole Corsini, Marie-Emmanuelle Morin-Meschin, Alain Lortholary, Claude Adenis, Audrey Maillez, Tan Dat Nguyen, Capucine Delnatte, Caroline Abadie, Julie Tinat, Isabelle Tennevet, Christine Maugard, Yves-Jean Bignon, Mathilde Gay Bellile, Clotilde Penet, Hélène Dreyfus, Odile Cohen-Haguenauer, Brigitte Gilbert, Laurence Venat-Bouvet, Dominique Leroux, Clémentine Legrand, Hélène Zattara-Cannoni, Valérie Layet, Elodie Lacaze, Sandra Fert-Ferrer, Odile Bera, Brigitte Gilbert-Dussardier, David Tougeron, Hakima Lallaoui, M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, M.A. Adank, M.K. Schmidt, D.J. Jenner, J.M. Collée, A.M.W. van den Ouweland, M.J. Hooning, I.A. Boere, C.J. van Asperen, P. Devilee, R.B. van der Luijt, T.C.T.E.F. van Cronenburg, M.R. Wevers, A.R. Mensenkamp, M.G.E.M. Ausems, M.J. Koudijs, I. van de Beek, K. van Engelen, J.J.P. Gille, E.B. Gómez García, M.J. Blok, M. de Boer, L.P.V. Berger, A.H. van der Hout, M.J.E. Mourits, G.H. de Bock, S. Siesling, J. Verloop, E.C. van den Broek

Publikováno v: American Journal of Obstetrics and Gynecology, 225(1), 51.e1-51.e17. MOSBY-ELSEVIER
Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study 2021, ' Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study ', American Journal of Obstetrics and Gynecology, vol. 225, no. 1, pp. 51.e1-51.e17 . https://doi.org/10.1016/j.ajog.2021.01.014
American Journal of Obstetrics and Gynecology, 225, 51.e1-51.e17
American Journal of Obstetrics and Gynecology, 225(1), 51.e1-51.e17. Mosby Inc.
American Journal of Obstetrics and Gynecology
American Journal of Obstetrics and Gynecology, 2021, 225 (1), pp.51.e1-51.e17. ⟨10.1016/j.ajog.2021.01.014⟩
American journal of obstetrics and gynecology, 225(1), 51.e1-51.e17. Mosby Inc.
Schrijver, L H, Antoniou, A C, Olsson, H, Mooij, T M, Roos-Blom, M J, Azarang, L, Adlard, J, Ahmed, M, Barrowdale, D, Davidson, R, Donaldson, A, Eeles, R, Evans, D G, Frost, D, Henderson, A, Izatt, L, Ong, K R, Bonadona, V, Coupier, I, Faivre, L, Fricker, J P, Gesta, P, van Engelen, K, Jager, A, Menko, F H, Mourits, M J E, Singer, C F, Tan, Y Y, Foretova, L, Navratilova, M, Schmutzler, R K, Ellberg, C, Gerdes, A M, Caldes, T, Simard, J, Olah, E, Jakubowska, A, Rantala, J, Osorio, A, Hopper, J L, Phillips, K A, Milne, R L, Beth Terry, M, Noguès, C, Engel, C, Kast, K, Goldgar, D E, van Leeuwen, F E, Easton, D F, Andrieu, N, Rookus, M A & Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study 2021, ' Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study ', American Journal of Obstetrics and Gynecology, vol. 225, no. 1, pp. 51.e1-51.e17 . https://doi.org/10.1016/j.ajog.2021.01.014
EMBRACE, GENEPSO, HEBON, IBCCS & et al. 2021, ' Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study ', American Journal of Obstetrics and Gynecology . https://doi.org/10.1016/j.ajog.2021.01.014
American Journal of Obstetrics and Gynecology, 225, 1, pp. 51.e1-51.e17

Contains fulltext : 237895.pdf (Publisher’s version ) (Open Access) BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679a56d0abad49f333383dc486d3e8ab
http://www.ajog.org/article/S0002937821000387/pdf

Calibration of pathogenicity due to variant-induced leaky splicing defects by using BRCA2 exon 3 as a model system

Autor: Gaia Castelain, Capucine Delnatte, Pascaline Gaildrat, Myriam Vezain, Laëtitia Meulemans, Nadia Boutry-Kryza, Teresa Sullivan, Dominique Stoppa-Lyonnet, Julie Hauchard, Pascal Pujol, Thierry Frebourg, Séverine Audebert-Bellanger, Daniela Di Giacomo, Danièle Muller, Aurélie Drouet, Hélène Tubeuf, Susan W. Reid, Julie Rondeaux, Mélanie Léoné, Violaine Bourdon, Françoise Bonnet-Dorion, Françoise Révillion, Hélène Larbre, Shyam K. Sharan, Omar Soukarieh, Sandrine M. Caputo, Alice Fiévet, Laurence Venat-Bouvet, Virginie Caux-Moncoutier, Alexandra Martins, Fátima Vaz, Angela R. Solano, Claude Houdayer, Eileen Southon, Chrystelle Colas, Marine Guillaud-Bataille, Linda Cleveland, Sophie Krieger

Publikováno v: Cancer Res
Cancer Research
Cancer Research, 2020, 80 (17), pp.3593-3605. ⟨10.1158/0008-5472.CAN-20-0895⟩

BRCA2 is a clinically actionable gene implicated in breast and ovarian cancer predisposition that has become a high priority target for improving the classification of variants of unknown significance (VUS). Among all BRCA2 VUS, those causing partial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f68c10d8df37aff88dc3d1287374cd2
https://europepmc.org/articles/PMC7484206/

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

Autor: Stephen P. Jackson, Mareike Herzog, Alejandra Bruna, Luca Pellegrini, Violeta Serra, Mark J. O'Connor, Zhongwu Lai, Chloé Lescale, Jacqueline J.L. Jacobs, Fengtang Yang, Jonathan Lam, Matylda Sczaniecka-Clift, Abigail Shea, Carlos Caldas, Matthias Ostermaier, Gabriel Balmus, Julia Coates, Wenming Wei, Inge de Krijger, Yaron Galanty, Mukerrem Demir, Ludovic Deriano, Petra Beli, Domenic Pilger, Harveer Dev, Rimma Belotserkovskaya, Alistair Martin, Beiyuan Fu, Ting-Wei Will Chiang, Qian Wu

Publikováno v: Nature Cell Biology
Nature Cell Biology, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩
Nature cell biology
Nature Cell Biology, Nature Publishing Group, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩

International audience; BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome CRISP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c03882fb1aad0056e71d15c34e8ed4
https://www.repository.cam.ac.uk/handle/1810/282947

Les tumeurs borderline de l’ovaire de stade avancé : facteurs pronostiques et place du traitement conservateur

Autor: Maria, Sophie

Publikováno v: Médecine humaine et pathologie. 2019

Background: the aim of this study was to assess prognostic factors and conservative treatment in patients with stage II or III serous borderline ovarian tumors (SBOT) after a long term follow up in a large series. Methodology: patients with SBOT and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2592::0d4e89efdfbd77b7ba67c74f3bb50c61
https://dumas.ccsd.cnrs.fr/dumas-03205365/document